SEC Form 4 · accession 0001209191-15-079481
Endo International plc · ENDP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Campanelli
Officer — President, Par Pharmaceutical
Period of report
Nov 11, 2015
Accepted (ET)
Nov 12, 2015 · 7:35 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001593034
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 11, 2015 | P | 1,900 | $55.62 | A | 187,869 | D | |
| Ordinary SharesF2 | Nov 11, 2015 | P | 200 | $56.38 | A | 188,069 | D | |
| Stock Incentive Plan Performance SharesF3,F4,F5,F6 | Nov 11, 2015 | A | 2,100 | — | A | 105,466 | D | |
| Stock Incentive Plan Restricted Stock Units (RSU)F7 | holding | — | — | — | 15,367 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents the average price per share of ordinary shares that Mr. Campanelli bought on the open market on November 11, 2015 at prices ranging from $55.22 to $56.17.
- F2This represents the average price per share of ordinary shares that Mr. Campanelli bought on the open market on November 11, 2015 at prices ranging from $56.34 to $56.41.
- F3The performance shares vest upon the Company achieving certain shareholder return targets over a cumulative 3-year period.
- F4Represents the target number of shares issuable upon achievement of a certain shareholder return target over a cumulative 3-year period, as determined by the Registrant's Board of Directors at the end of such three-year period. The ultimate number of shares issued may be the target number or zero, depending on the Registrant's attainment of the shareholder return target over the period.
- F5Pursuant to the Endo International plc Matched Performance Share Unit Program, the Registrant matched Mr. Campanelli's open market purchases of ordinary shares, subject to certain limitations, which occurred on November 11, 2015, as reported above. These securities were granted to Mr. Campanelli in consideration of his services as the President, Par Pharmaceutical of Endo International plc.
- F6Represents the cumulative target quantity of shares issuable with respect to all 2010 and 2015 Stock Incentive Plan performance shares outstanding. The cumulative total is the combination of the target payouts for the current grant and all past grants made under the 2010 Stock Incentive Plan and the 2015 Stock Incentive Plan and still outstanding, which are subject to a range of payouts depending on the achievement of certain performance metrics as described herein for the current grant and as previously disclosed for all other performance share grants.
- F7Subject to time-based vesting, each restricted stock automatically converts into one (1) ordinary share of Endo International plc.